Range Capital Acquisition Corp II 3Q 2026: Net income $2.03M — 10-Q Summary

Range Capital Acquisition Corp II reported net income of $2.03M for the quarter, reversing a $37.36K loss from the prior year, driven by trust-account interest and bank investment income. The company has not yet selected a target for a business combination. As of September 30, 2026, its trust account held $238.4M in marketable securities, with $695,103 in cash outside the trust account.

Original reporting
Published Nov 13, 2026, 7:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 7:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Range Capital Acquisition Corp II 3Q 2026: Net income $2.03M — 10-Q Summary — source image
Decision brief

The 30-second read

$RNGTNeutralLow
01

Why it matters

The filing offers a rare profit signal for a SPAC still in the search phase, but the lack of operational revenue and limited cash outside the trust limit immediate upside.

02

Market read

Provides a modest profit update for a micro‑cap SPAC, with limited trading relevance beyond niche investors.

03

What to watch

The sizable trust account ($238.4M) provides a runway, but the cash outside the trust is insufficient for a year, raising questions about timing of a merger.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Range Capital Acquisition Corp II (RNGT) is a special purpose acquisition company that has not yet identified a merger target. The 10‑Q filing reports a small net profit and details of its trust account and liquidity position.

Company-level read

Ticker impact

$RNGTNeutralMedium confidence
Context

10-Q filing shows the SPAC posted a $2.03M net income versus a loss a year ago, the first profit report for the company.

Expected impact

likely slight upward pressure as the market prices in the first profit, but limited by lack of revenue and ongoing cash constraints

Evidence & confidence

Profit is modest and the company still has no operations; investors may view the result as a technical win but remain cautious.

Market effects

Minimal impact on the broader SPAC sector; the filing underscores typical cash‑burn concerns for blank‑check companies.

U.S. market only; no broader regional effect.

Low; the news is specific to a micro‑cap SPAC.

Counterpoint

Investors could short the SPAC anticipating that the lack of a business combination target will lead to liquidation risk.

Key entities

  • Range Capital Acquisition Corp II

    SPAC awaiting a business combination.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.